Twinrix

Twinrix Liều dùng/Hướng dẫn sử dụng

vaccine, hepatitis a + hepatitis b

Nhà sản xuất:

GlaxoSmithKline
Thông tin kê toa chi tiết tiếng Anh
Dosage/Direction for Use
Dosage: A dose of 1.0 ml Twinrix is recommended for adults, adolescents and children aged from 1 year upwards.
Primary vaccination schedules: Adults and adolescents of 16 years of age and above: The standard primary course of vaccination with Twinrix consists of three doses, the first administered at the elected date, the second one month later and the third six months after the first dose.
In exceptional circumstances in adults, when travel is anticipated within one month or more after initiating the vaccination course, but where insufficient time is available to allow the standard 0, 1, 6 month schedule to be completed, a schedule of three intramuscular injections given at 0, 7 and 21 days may be used. When this schedule is applied, a fourth dose is recommended 12 months after the first dose.
Children of 1 to 15 years of age: The standard primary course of vaccination with Twinrix consists of two doses, the first is administered at the elected date and the second between six and twelve months after the first dose. As protection against hepatitis B infection will not be obtained in all vaccinees until after the second dose, it is important that the second dose be administered to assure protection against hepatitis B infection.
The recommended schedule should be adhered to. Once initiated, the primary course of vaccination should be completed with the same vaccine.
Booster dose: Long-term antibody persistence data following vaccination with Twinrix in adults with a 0, 1, 6 month schedule are available for up to 15 years after vaccination.
The anti-HBs and anti-HAV antibody titres observed following a primary vaccination course with the combined vaccine are in the range of what is seen following vaccination with the monovalent vaccines. Following vaccination with Twinrix in adults, the kinetics of antibody decline are similar to what has been observed after vaccination with the monovalent vaccines. General guidelines for booster vaccination can therefore be drawn from experience with the monovalent vaccines.
Hepatitis B: The need for a booster dose of hepatitis B vaccine in healthy individuals who have received a full primary vaccination course has not been established; however some official vaccination programmes currently include a recommendation for a booster dose of hepatitis B vaccine and these should be respected.
For some categories of subjects or patients exposed to HBV (e.g. haemodialysis or immunocompromised patients) a precautionary attitude should be considered to ensure a protective antibody level ≥10 IU/l.
Hepatitis A: It is not yet fully established whether immunocompetent individuals who have responded to hepatitis A vaccination will require booster doses, as protection in the absence of detectable antibodies may be ensured by immunological memory. Guidelines for boosting are based on the assumption that antibodies are required for protection; anti-HAV antibodies have been shown to persist for at least 10 years.
In situations where a booster dose of both hepatitis A and hepatitis B are desired, Twinrix can be given. Alternatively, subjects primed with Twinrix may be administered a booster dose of either of the monovalent vaccines. The safety and immunogenicity of Twinrix administered as a booster dose following a two dose primary vaccination course have not been evaluated.
Method of Administration: Twinrix should be injected intramuscularly into the deltoid region of the upper arm in adults, adolescents and children. The anterolateral thigh may be used in infants.
Since intradermal injection or intramuscular administration into the gluteal muscle could lead to a suboptimal response to the vaccine, these routes should be avoided. Exceptionally, Twinrix can be administered subcutaneously to subjects with thrombocytopenia or bleeding disorders since bleeding may occur following an intramuscular administration to these subjects. However, this route of administration may result in suboptimal immune response to the vaccine.
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in